𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

✍ Scribed by Josef S Smolen; Jonathan Kay; Mittie K Doyle; Robert Landewé; Eric L Matteson; Jürgen Wollenhaupt; Norman Gaylis; Frederick T Murphy; Jeffrey S Neal; Yiying Zhou; Sudha Visvanathan; Elizabeth C Hsia; Mahboob U Rahman

Book ID
117304548
Publisher
The Lancet
Year
2009
Tongue
English
Weight
222 KB
Volume
374
Category
Article
ISSN
0140-6736

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Golimumab, a human anti–tumor necrosis f
Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four–week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis
✍ Paul Emery; Roy M. Fleischmann; Larry W. Moreland; Elizabeth C. Hsia; Ingrid Str 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB 👁 1 views
Erratum: Golimumab, a human anti-tumor n
Erratum: Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis
✍ Paul Emery; Roy M. Fleischmann; Larry W. Moreland; Elizabeth C. Hsia; Ingrid Str 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 38 KB 👁 1 views